Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04718896 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
A Phase 2 study of Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 11
- Study locations
NCT04718896: Completed Phase 2 study of Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL.
NCT04718896 is a Phase 2 study of Moderate to Severe Plaque Psoriasis that has completed, run by UCB Biopharma SRL. The registered enrollment target is 41 participants, below the 93-participant average among 3 other Moderate to Severe Plaque Psoriasis trials with a reported enrollment target (56% lower). The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04718896, a Phase 2 study of Moderate to Severe Plaque Psoriasis, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Primary Outcome
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 0. PK-PPS = Pharmacokinetic per-protocol set, IMP = investigational medicinal product.
Conditions Studied
Interventions
- DRUG bimekizumab
Study Locations (11)
Other
- Ps0020 50354 - Calgary
- Ps0020 50357 - St. John's
- Ps0020 40645 - Frankfurt
- Ps0020 40626 - Bialystok
- Ps0020 40625 - Lodz
- Ps0020 40396 - Rzeszów
- Ps0020 40335 - Warsaw
- Ps0020 40333 - Wroclaw
- Ps0020 40334 - Wroclaw
Indiana
- Ps0020 50344 - Indianapolis
Texas
- Ps0020 50359 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2025-03-12 |
| Phase | Phase 2 |
What the finished NCT04718896 record still lists
NCT04718896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 93-participant average among 3 other Moderate to Severe Plaque Psoriasis trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Moderate to Severe Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which bimekizumab is the first listed.
NCT04718896 lists 11 locations in 3 states (Other, Indiana, Texas).
Frequently Asked Questions
What is clinical trial NCT04718896 about?
NCT04718896 is a clinical study titled "A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis". The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
What is the current status of trial NCT04718896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-04-06. Estimated completion is 2025-03-12.
What conditions does trial NCT04718896 study?
This clinical trial studies the following conditions: Moderate to Severe Plaque Psoriasis.
What interventions are being tested in trial NCT04718896?
The interventions under investigation include: bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04718896?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04718896 being conducted?
This trial has 11 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI